1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Tarceva Forecast

Tarceva Forecast

  • May 2014
  • -
  • BCC Research
  • -
  • 36 pages

The BCC Research Tarceva Forecast is a quantitative forecast model in an easily accessible Microsoft Excel spreadsheet, segmented by specific parameters.

The introductory sample of the Tarceva Forecast Model was already sent in the update earlier today. I have attached it again for your reference.

The model features:

- Market demand forecasts for Tarceva annually for the years 2010 to 2030 by volume (number of patients) and value (in U.S. dollars)
- Segmentation of volume and value for the following regions: U.S., Japan, Europe, Latin America, China, Asia, Middle East
- Patient volumes, with forecasts by causal factors including population by age range, smoker data, and prevalence

Click here to view a data sheet of the Tarceva Forecast Model.

Use the BCC Research Tarceva Forecast to:

- Examine forecasted market demand for Tarceva: competitor assessment; market opportunity assessment
- Identify new business and investment opportunities for products in the lung cancer segment
- Validate other Tarceva market-demand data to which you have access

Tarceva Forecast, a strategic investment product designed to provide critical market data for the pharmaceutical cancer drug Tarceva.
 
Tarveca (Astellas Pharma) is a once-daily, oral, non-chemotherapy prescription drug for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). Some clinical studies have shown superior patient outcomes from use of Tarceva as a second-line treatment for NSCLC. Starting in 2020, Tarceva begins to lose patent protection in numerous countries.
 
Through Tarceva Forecast, BCC Research provides high-quality intelligence for strategic decision-making regarding future participation in this large and important market. Market players can use Tarceva Forecast to examine forecasted market demand for Tarceva, identify new business and investment opportunities for related products and services, and validate other Tarceva market-demand data.
 
Tarceva Forecast is a quantitative forecast model in an easily accessible Microsoft Excel spreadsheet, segmented by specific parameters, featuring market demand forecasts for Tarceva annually for the years 2010 to 2030 by volume and value. Data transparency and sources are disclosed for patient volumes, with forecasts by causal factors including population by age range, smoker data, and prevalence, as well as for population estimates at the country level and product pricing and currency valuation forecasts. Information is segmented by the following regions:  United States, Japan, Europe, Latin America, China, Asia, Middle East.

Table Of Contents

Tarceva Forecast
Table of Contents

Figure 1 Summary Graphs - Value in U.S.D. and Patient Volumes, by Region, 2010-2030
Table 1 Total Market - Value in U.S.D. and Patient Volumes, by Region, 2010-2030
Table 2 United States Patient Volumes, 2010-2030
Table 3 Europe Patient Volumes, 2010-2030
Table 4 Japan Patient Volumes, 2010-2030
Table 5 China Patient Volumes, 2010-2030
Table 6 Asia Patient Volumes, 2010-2030
Table 7 Africa/Oceania Patient Volumes, 2010-2030
Table 8 Middle East Patient Volumes, 2010-2030
Table 9 Americas Patient Volumes, 2010-2030
Table 10 United States Population by age range, 2010-2030
Table 11 Europe Population by Country, 2010-2030
Table 12 Japan Population, 2010-2030
Table 13 China Population, 2010-2030
Table 14 Asia Population by Country, 2010-2030
Table 15 Africa/Oceania Population by Country, 2010-2030
Table 16 Middle East Population by Country, 2010-2030
Table 17 Americas Population by Country, 2010-2030
Table 18 United States Smoker Data
Table 19 Europe Smoker Data by Country
Table 20 Japan Smoker Data
Table 21 China Smoker Data
Table 22 Asia Smoker Data by Country
Table 23 Africa/Oceania Smoker Data by Country
Table 24 Middle East Smoker Data by Country
Table 25 Americas Smoker Data by Country
Table 26 United States Lung Cancer Data, 1975-2010
Table 27 Global Lung Cancer Data, by Male and Female, by Region
Table 28 United States Pricing, Tarceva Annual Cost
Table 29 Europe Pricing and FX Rate, Tarceva Annual Cost, Currency Conversion Rates 2011-2014
Table 30 Japan Pricing and FX Rate, Tarceva Annual Cost, Currency Conversion Rates 2011-2014
Table 31 China Pricing and FX Rate, Tarceva Annual Cost, Currency Conversion Rates 2011-2014
Table 32 Asia Pricing and FX Rate, Tarceva Annual Cost, Currency Conversion Rates 2011-2014
Table 33 Africa/Oceania Pricing and FX Rate, Tarceva Annual Cost, Currency Conversion Rates 2011-2014
Table 34 Middle East Pricing and FX Rate, Tarceva Annual Cost, Currency Conversion Rates 2011-2014
Table 35 Americas Pricing and FX Rate, Tarceva Annual Cost, Currency Conversion Rates 2011-2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts

  • $ 5995
  • Industry report
  • December 2016
  • by GlobalData

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts Summary Companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows ...


Download Unlimited Documents from Trusted Public Sources

Hormone and Therapy Market in Pakistan and the US

  • March 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Cancer Statistics in the Netherlands and the US

  • March 2017
    19 pages
  • Cancer  

    Hospital  

  • Netherlands  

    United States  

View report >

Lymphoma Statistics in Germany

  • March 2017
    167 pages
  • Lymphoma  

    Cancer  

    Leukemia  

  • Germany  

    Europe  

    United States  

View report >

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.